Literature DB >> 3317416

Defective HLA class II expression in a regulatory mutant is partially complemented by activated ras oncogenes.

C R Hume1, R S Accolla, J S Lee.   

Abstract

The human B-cell line RJ2.2.5, derived by mutagenesis from a Burkitt lymphoma cell line and selected for loss of HLA class II antigen expression, was infected with recombinant retroviruses containing either the Harvey murine sarcoma virus oncogene v-Ha-ras or the human neuroblastoma homolog NRAS. Both activated ras genes partially complemented the regulatory defect in RJ2.2.5 and specifically increased the expression of the DR and DQ subsets of HLA class II genes. Blot-hybridization analysis and RNase mapping indicated that HLA-DQ alpha-chain mRNA in the infected cell lines was increased to a level at least 50% that of the parent B-cell line, Raji. The levels of HLA-DR and -DQ beta-chain RNA also were increased but to a lesser extent. In contrast, we detected no effect of ras on the quantities of other class II, class I, or invariant-chain mRNAs. Fluorescence-activated cell sorter analysis with antibodies recognizing HLA-DR, -DQ, and class I antigens supported these observations. Enhancement of HLA class II gene expression by ras genes may have important implications for regulation of the immune system in response to transformation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317416      PMCID: PMC299593          DOI: 10.1073/pnas.84.23.8603

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  The human Ia system.

Authors:  R J Winchester; H G Kunkel
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

3.  A rapid and improved method for generating cDNA libraries in plasmid and phage lambda vectors.

Authors:  S Sartoris; E B Cohen; J S Lee
Journal:  Gene       Date:  1987       Impact factor: 3.688

4.  Transcription maps of polyoma virus-specific RNA: analysis by two-dimensional nuclease S1 gel mapping.

Authors:  J Favaloro; R Treisman; R Kamen
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

5.  Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer.

Authors:  A K Sood; D Pereira; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

6.  The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes.

Authors:  R W Ellis; D Defeo; T Y Shih; M A Gonda; H A Young; N Tsuchida; D R Lowy; E M Scolnick
Journal:  Nature       Date:  1981-08-06       Impact factor: 49.962

7.  Identification of a trans-acting function regulation HLA-DR expression in a DR-negative B cell variant.

Authors:  P Gladstone; D Pious
Journal:  Somatic Cell Genet       Date:  1980-03

8.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

9.  Increased expression of I-region-associated antigen (Ia) on B cells after cross-linking of surface immunoglobulin.

Authors:  J J Mond; E Seghal; J Kung; F D Finkelman
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

10.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

View more
  10 in total

Review 1.  Interactions between immunogenic peptides and HLA-DR molecules.

Authors:  J B Rothbard; R Busch
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 2.  Genetics of HLA class II regulation.

Authors:  C R Hume; J S Lee
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  HLA class II mRNA accumulation by activated human T cells following growth in conditioned medium.

Authors:  B Gansbacher; K S Zier
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

4.  Alternative splicing of HLA-DQB transcripts and secretion of HLA-DQ beta-chain proteins: allelic polymorphism in splicing and polyadenylylation sites.

Authors:  P Briata; S F Radka; S Sartoris; J S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  Conserved upstream sequences of human class II major histocompatibility genes enhance expression of class II genes in wild-type but not mutant B-cell lines.

Authors:  J H Sloan; J M Boss
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Induction of intercellular adhesion molecule 1 and class II histocompatibility antigens in colorectal tumour cells expressing activated ras oncogene.

Authors:  V Stoneman; A Morris
Journal:  Clin Mol Pathol       Date:  1995-12

7.  mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element.

Authors:  L B Ivashkiv; H C Liou; C J Kara; W W Lamph; I M Verma; L H Glimcher
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

8.  Sequential changes in MHC antigen expression induced by the v-Ki-ras oncogene.

Authors:  R L Darley; A G Morris
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

9.  An enhancer factor defect in a mutant Burkitt lymphoma cell line.

Authors:  W Koch; S Candeias; J Guardiola; R Accolla; C Benoist; D Mathis
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Transcriptional enhancement of the human gene encoding for a melanoma-associated antigen (ME491) in association with malignant transformation.

Authors:  H Hotta; N Takahashi; M Homma
Journal:  Jpn J Cancer Res       Date:  1989-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.